Hormone replacement therapy and risk of breast cancer: the role of progestins
暂无分享,去创建一个
[1] E. Weiderpass,et al. Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement , 1999, Cancer Causes & Control.
[2] J. Eden. Progestins and breast cancer. , 2003, American journal of obstetrics and gynecology.
[3] M. C. Terek,et al. Mammographic density changes during different postmenopausal hormone replacement therapies. , 2001, Fertility and sterility.
[4] J. Flaws,et al. Hormone Replacement Therapy and Breast Cancer: A Qualitative Review , 2001, Obstetrics and gynecology.
[5] H. Olsson,et al. A population-based cohort study of HRT use and breast cancer in southern Sweden , 2001, British Journal of Cancer.
[6] S. Hunskaar,et al. Increased acceptance of HRT and improved level of information: a change in Norwegian women's opinion from 1990 to 1997 , 2001, Acta obstetricia et gynecologica Scandinavica.
[7] S. Haslam,et al. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model , 2001, Journal of cellular physiology.
[8] T. Bush,et al. Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.
[9] G. Colditz,et al. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.
[10] H. Adami,et al. More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.
[11] M. Pike,et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.
[12] G. Berntsen,et al. Hormone replacement therapy: knowledge, attitudes, self-reported use - and sales figures in Nordic women. , 2000, Maturitas.
[13] R. Millikan,et al. Menopausal hormones and breast cancer in a biracial population. , 2000, American journal of public health.
[14] R. Hoover,et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.
[15] C. Campagnoli,et al. HRT and breast cancer risk: a clue for interpreting the available data. , 1999, Maturitas.
[16] K. Heck,et al. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. , 1999, American journal of preventive medicine.
[17] P. Kenemans,et al. Hormonal prevention of breast cancer: proposal for a change in paradigm , 1999, British journal of obstetrics and gynaecology.
[18] C. la Vecchia,et al. Risk factors for breast cancer in women under 40 years. , 1999, European journal of cancer.
[19] B. V. VON Schoultz,et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. , 1999, American journal of obstetrics and gynecology.
[20] V. Beral,et al. Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.
[21] H. Adami,et al. Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.
[22] U. Bergman,et al. Low use of long-term hormone replacement therapy in Denmark. , 1999, British journal of clinical pharmacology.
[23] Linda Olson,et al. Effects of Estrogen and EstrogenProgestin on Mammographic Parenchymal Density , 1999, Annals of Internal Medicine.
[24] T. Lancaster,et al. Hormone replacement therapy: patterns of use studied through British general practice computerized records. , 1999, Family practice.
[25] J. Townsend,et al. Hormone replacement therapy: assessment of present use, costs, and trends. , 1998, The British journal of general practice : the journal of the Royal College of General Practitioners.
[26] Svend Kreiner,et al. Hormone replacement therapy and risk of non-fatal stroke , 1997, The Lancet.
[27] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[28] H. Mouridsen,et al. Time since childbirth and prognosis in primary breast cancer: population based study , 1997, BMJ.
[29] K. Horwitz,et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.
[30] D. Ciocca,et al. Estrogen Receptors and Cell Proliferation in Breast Cancer , 1997, Trends in Endocrinology & Metabolism.
[31] I Persson,et al. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Holmberg,et al. Hormone replacement therapy and the risk of breast cancer. Nested case‐control study in a cohort of Swedish women attending mammography screening , 1997, International journal of cancer.
[33] L. Mattsson,et al. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population , 1997, Acta obstetricia et gynecologica Scandinavica.
[34] J. Madans,et al. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. , 1997, American journal of epidemiology.
[36] H. Schneider,et al. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. , 1997, International journal of fertility and women's medicine.
[37] F. Olesen,et al. A comparative study of prescribing of hormone replacement therapy in USA and Europe. , 1996, Maturitas.
[38] A. Holte,et al. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. , 1995, Maturitas.
[39] A. Miller,et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. , 1995, Journal of the National Cancer Institute.
[40] J. Russo,et al. The etiopathogenesis of breast cancer prevention. , 1995, Cancer letters.
[41] H. Adami,et al. Transient increase in the risk of breast cancer after giving birth. , 1994, The New England journal of medicine.
[42] R. Dickson,et al. Progestins and antiprogestins in mammary tumour growth and metastasis. , 1994, Human reproduction.
[43] G. Colditz,et al. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. , 1993, American journal of obstetrics and gynecology.
[44] M. Pike,et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.
[45] S. Thacker,et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. , 1991, JAMA.
[46] C. Clarke,et al. Progestin regulation of cellular proliferation. , 1990, Endocrine reviews.
[47] M. Ewertz. Influence of non‐contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark , 1988, International journal of cancer.
[48] S. Kjaer,et al. Ovarian cancer incidence and mortality in denmark, 1943‐1982 , 1988, International journal of cancer.
[49] T. Longacre,et al. A Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle , 1986, The American journal of surgical pathology.